Revenue
2024
Maze Therapeutics, Inc. (MAZE)
Price—Loading quote
Net income
2024
2025
Free cash flow
2024
2025
Total cash / debt
CashTotal debt
2023
2024
2025
Financial statements
| 2025 | 2024 | |
|---|---|---|
| Revenue | — | $167.5M |
| Research & development | $108.4M | $83.5M |
| Operating expenses | $142.9M | $109.9M |
| Operating income | −$142.9M | $57.6M |
| Net income | −$131.1M | $52.2M |
| Basic EPSper diluted share | -$3.05 | $1.42 |
| Diluted EPSper diluted share | -$3.05 | $1.25 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Coloma Jason VChief Executive Officer | SellCommon Stock · indirect | 23.9K | $26.05 | $621.7K | 319.1K |
| Jun 22, 2026Form 4 · 10b5-1 | Coloma Jason VChief Executive Officer | SellCommon Stock · indirect | 2.0K | $26.00 | $53.0K | 25.9K |
| Jun 22, 2026Form 4 · 10b5-1 | Coloma Jason VChief Executive Officer | SellCommon Stock · indirect | 2.0K | $26.00 | $50.8K | 342.9K |
| Jun 1, 2026Form 4 · 10b5-1 | Bernstein HaroldPresident, R&D & CMO | SellCommon Stock | 1.6K | $26.36 | $42.2K | 0 |
| Jun 1, 2026Form 4 · 10b5-1 | Bernstein HaroldPresident, R&D & CMO | SellCommon Stock | 13.3K | $25.57 | $338.9K | 1.6K |